CARA - Cara Therapeutics wins CMS grants for newly approved pruritus therapy

Cara Therapeutics (NASDAQ:CARA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) greenlighted a form of reimbursement for KORSUVA (difelikefalin) injection in the anti-pruritic functional category. The Transitional Drug Add-On Payment Adjustment (TDAPA) issued for KORSUVA (difelikefalin) will take effect from April 04, 2022, the company said. Informing its decision, CMS noted that KORSUVA injection was  only the second product to be approved for TDAPA. “Receiving TDAPA from CMS is a crucial step toward the commercial launch of KORSUVA injection, which we believe will benefit thousands of chronic kidney disease patients undergoing dialysis who suffer from pruritus,” CEO Christopher Posner remarked. Cara and its partner Vifor, remain on track for the U.S. commercial launch of the drug in Q2 2022. In August, KORSUVA was granted the FDA approval for moderate-to-severe pruritus linked to  chronic kidney disease in adults undergoing hemodialysis.

For further details see:

Cara Therapeutics wins CMS grants for newly approved pruritus therapy